KalVista Pharmaceuticals

creating a new generation of small molecule protease inhibitors for HAE and DME

KalVista Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference

KalVista Pharmaceuticals Announces the Closing of its Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

KalVista Pharmaceuticals Announces Pricing of an Upsized $193.5 Million Public Offering of Common Stock